Pembrolizumab is used to treat triple-negative breast cancer, an aggressive form of the disease which disproportionately affects under-40s, and will be offered to local breast cancel patients “who fit specific treatment criteria”. The National Institute for Health and Care Excellence (NICE) recently approved the use of the drug – which they say can make cancer “disappear” – […]
